Rhumbline Advisers Trims Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Rhumbline Advisers trimmed its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,838 shares of the company’s stock after selling 9,410 shares during the quarter. Rhumbline Advisers owned about 0.15% of Intellia Therapeutics worth $1,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of NTLA. Empowered Funds LLC purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at approximately $185,000. Allspring Global Investments Holdings LLC grew its stake in shares of Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after buying an additional 1,582 shares during the last quarter. LMG Wealth Partners LLC bought a new position in Intellia Therapeutics during the 4th quarter valued at approximately $130,000. Handelsbanken Fonder AB raised its stake in Intellia Therapeutics by 7.1% during the fourth quarter. Handelsbanken Fonder AB now owns 34,700 shares of the company’s stock valued at $405,000 after buying an additional 2,300 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Intellia Therapeutics during the fourth quarter valued at $304,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on NTLA shares. Chardan Capital reissued a “buy” rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. Canaccord Genuity Group dropped their price target on shares of Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, June 3rd. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. JPMorgan Chase & Co. restated a “neutral” rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Finally, Wolfe Research upgraded shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.95.

Intellia Therapeutics Trading Up 0.2%

NASDAQ:NTLA opened at $9.60 on Friday. The company has a market cap of $994.37 million, a PE ratio of -1.84 and a beta of 2.14. The company has a 50 day simple moving average of $8.24 and a two-hundred day simple moving average of $9.74. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the previous year, the company posted ($1.12) earnings per share. Intellia Therapeutics’s revenue was down 42.6% compared to the same quarter last year. Research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.